Journal Watch
- PDF / 85,550 Bytes
- 5 Pages / 592.44 x 751.18 pts Page_size
- 40 Downloads / 142 Views
NEWS
© 2007 Adis Data Information BV. All rights reserved.
Journal Watch1 Contents 1. 2. 3. 4. 5. 6. 7. 8.
Potential of Gene Expression Profiling in the Management of Childhood Acute Lymphoblastic Leukemia . . . . . . . . . . . . . . . . . . . . 407 Emerging Treatments and Gene Expression Profiling in High-Risk Medulloblastoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 407 Does Glycoprotein IIIa Gene (PlA) Polymorphism Influence Clopidogrel Resistance? A Study in Older Patients . . . . . . . . . . . . . . . . 408 Clinical Translation of Genotyping and Haplotyping Data: Implementation of In Vivo Pharmacology Experience Leading Drug Prescription to Pharmacotyping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 408 Safety, Pharmacokinetics and Pharmocodynamics of Recombinant Human Porphobilinogen Deaminase in Healthy Subjects and Asymptomatic Carriers of the Acute Intermittent Porphyria Gene Who Have Increased Porphyrin Precursor Excretion . . . . . 409 Incorporating Genome-Based Technologies into Toxicology and Safety Assessments for Drug Discovery and Development . . . 410 Influence of Cytochrome P450 (CYP) 3A5 Polymorphisms on the Pharmacokinetics of Lansoprazole Enantiomers in CYP2C19 Extensive Metabolizer Renal Transplant Recipients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 410 Various Pharmacogenetic Aspects of Antiepileptic Drug Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 410
1. Potential of Gene Expression Profiling in the Management of Childhood Acute Lymphoblastic Leukemia Childhood acute lymphoblastic leukemia (ALL) is a heterogeneous disease. Current treatment approaches are tailored according to the clinical features of the host, genotypic features of the leukemic blast, and early response to therapy. Although these approaches have been successful in dramatically improving outcomes, approximately 20% of children with ALL still relapse and many of these children do not have an identifiable adverse risk factor at presentation. Further insights into the biologic basis of the disease may contribute to novel, rational treatment strategies. Childhood ALL has served as an example for demonstrating the feasibility and potential of high-throughput technologies such as global gene expression or transcript profiling. In the last decade or so, utilization of these techniques has grown exponentially. As the methodology undergoes refinement and validation, it is plausible that microarrays may be used in the routine management of childhood ALL in the next few years. This article discusses the numerous applications to date of gene expression profiling in childhood ALL. Multiple investigators have made it evident that microarrays can be used as a single platform for the accurate classifi
Data Loading...
